Open for inclusion

A Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma

Cancer type: Melanoma

Phase: II

Principal Investigator: Nyakas Martha

Country: NO

Keywords: Norway, Oslo, UV1-202

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT04382664?titles=INITIUM&draw=2&rank=1